<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;B01A&quot;,&quot;href&quot;:&quot;atc/B01A.md&quot;},{&quot;label&quot;:&quot;nadroparin&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;Nadroparin_Chen2024_reference&quot;,&quot;label&quot;:&quot;Chen_2024_reference&quot;,&quot;href&quot;:&quot;drugs/drug_nadroparin/Nadroparin_Chen2024_reference.md&quot;,&quot;status&quot;:&quot;built, not shipped&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Nadroparin_Jaspers2022_reference&quot;,&quot;label&quot;:&quot;Jaspers_2022_reference&quot;,&quot;href&quot;:&quot;drugs/drug_nadroparin/Nadroparin_Jaspers2022_reference.md&quot;,&quot;status&quot;:&quot;built, not shipped&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Nadroparin_Piwowarczyk2023_shrinkage&quot;,&quot;label&quot;:&quot;Piwowarczyk_2023_shrinkage&quot;,&quot;href&quot;:&quot;drugs/drug_nadroparin/Nadroparin_Piwowarczyk2023_shrinkage.md&quot;,&quot;status&quot;:&quot;built, not shipped&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Nadroparin_Piwowarczyk2023_estimate_unit&quot;,&quot;label&quot;:&quot;Piwowarczyk_2023_estimate_unit&quot;,&quot;href&quot;:&quot;drugs/drug_nadroparin/Nadroparin_Piwowarczyk2023_estimate_unit.md&quot;,&quot;status&quot;:&quot;rejected&quot;,&quot;css&quot;:&quot;pk-badge--red&quot;,&quot;here&quot;:false}]"></div>

# nadroparin

- **generic name:** nadroparin
- **ATC codes:** `B01AB06`
- **DrugBank:** [DB08813](https://go.drugbank.com/drugs/DB08813) · **PubChem:** not captured
- **groups:** approved, investigational

## About

**Description.** Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. It is derived from porcine sources and has a mean molecular size of 5000 daltons. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

**Indication.** Nadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction.

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-05 20:29 | 8:34 | 3/1/0 | 1/0/0 | 0/0/0 | 98,703/19,325 | ollama / qwen3.8:27b-mtp-q8_0 | 3 | 0/3 | 3/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--orange">built, not shipped</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.571). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: model_quarantined: Cl, Vd, Tlag left at base-class defaults</sub><br><sub>route_to: `scholar`</sub> | [Chen_2024_reference](drugs/drug_nadroparin/Nadroparin_Chen2024_reference.md) | held back | 1-compartment, oral | 3 | Chen Y et al., Is the current therapeutic dosage of na…, Frontiers in pharmacology (2024) | [10.3389/fphar.2024.1331673](https://doi.org/10.3389/fphar.2024.1331673) |
| <span class="pk-badge pk-badge--orange">built, not shipped</span> <span class="pk-badge pk-badge--green" title="re-read by gpt-oss:120b (confirmed, agreement 1.0). The first reading is what the record holds.">cross-checked ✓</span><br><sub>caveat: the record defines covariate effects (weight on clearance, renal function …) but the engineer simulated only…</sub><br><sub>blocking: model_quarantined: Cl, Vd, ka, Tlag left at base-class defaults</sub><br><sub>route_to: `scholar`</sub> | [Jaspers_2022_reference](drugs/drug_nadroparin/Nadroparin_Jaspers2022_reference.md) | held back | 1-compartment, oral | 2 (+2 cov.) | Jaspers TCC et al., Optimising the Nadroparin Dose for Thro…, Clinical pharmacokinetics (2022) | [10.1007/s40262-022-01162-x](https://doi.org/10.1007/s40262-022-01162-x) |
| <span class="pk-badge pk-badge--orange">built, not shipped</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.375). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: model_quarantined: Vd left at base-class defaults</sub><br><sub>route_to: `scholar`</sub> | [Piwowarczyk_2023_shrinkage](drugs/drug_nadroparin/Nadroparin_Piwowarczyk2023_shrinkage.md) | held back | 1-compartment, IV | 1 | Piwowarczyk P et al., Population Pharmacokinetics and Probabi…, Clinical pharmacokinetics (2023) | [10.1007/s40262-023-01244-4](https://doi.org/10.1007/s40262-023-01244-4) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.6). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: C5 dimension mismatch on a structural parameter</sub><br><sub>route_to: `human_review`</sub> | [Piwowarczyk_2023_estimate_unit](drugs/drug_nadroparin/Nadroparin_Piwowarczyk2023_estimate_unit.md) | — | 1-compartment (no model) | 3 | Piwowarczyk P et al., Population Pharmacokinetics and Probabi…, Clinical pharmacokinetics (2023) | [10.1007/s40262-023-01244-4](https://doi.org/10.1007/s40262-023-01244-4) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.917). The first reading is what the record holds.">cross-check: disputed</span> | [Jaspers_2022_anti_Xa](drugs/drug_nadroparin/pd_Jaspers_2022_anti_Xa.md) | anti-Xa level ← nadroparin · stimulation effect | — | Jaspers TCC et al., Optimising the Nadroparin Dose for Thro…, Clinical pharmacokinetics (2022) | [10.1007/s40262-022-01162-x](https://doi.org/10.1007/s40262-022-01162-x) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=nadroparin) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| metabolism | liver | <sub>“…Nadroparin is metabolized in the liver.…”</sub> | prose |
| excretion | kidney | <sub>“…Nadroparin is eliminated via the kidneys through non-saturable mechanisms.…”</sub> | prose |

<sub>Actors without a tissue in the table: F10 (modulator), FOS (inhibitor), MYC (inhibitor), SELP (inhibitor), SERPINC1 (potentiator).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 10 matched, 10 returned
- **screened:** 5  ·  **relevant:** 5
- **records:** 4  ·  extracted 0  ·  needs_review 3  ·  rejected 1  ·  stale 0
- **scholar-agent fallback query used:** not captured

## Full text wanted

_3 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Laporte_1999.pdf` | Laporte S et al., Population pharmacokinetic of nadropari…, European journal of pharmac… (1999) | popPK | 10 | [10.1016/s0928-0987(98)00064-5](https://doi.org/10.1016/s0928-0987(98)00064-5) | [10210734](https://pubmed.ncbi.nlm.nih.gov/10210734) | The text explicitly provides the quantitative population PK model equations for apparent clearance and volume of distribution for nadroparin. |
| `Romano_2023.pdf` | Romano LGR et al., Population pharmacokinetics of nadropar…, British journal of clinical… (2023) | popPK | 10 | [10.1111/bcp.15634](https://doi.org/10.1111/bcp.15634) | [36495312](https://pubmed.ncbi.nlm.nih.gov/36495312) | The paper is a population PK study of nadroparin, but the specific numeric parameter values (e.g., typical CL, V, ka) are not present in the provided abstract text. |
| `Diepstraten_2015.pdf` | Diepstraten J et al., Population pharmacodynamic model for lo…, European journal of clinica… (2015) | popPK | 9 | [10.1007/s00228-014-1760-4](https://doi.org/10.1007/s00228-014-1760-4) | [25304008](https://pubmed.ncbi.nlm.nih.gov/25304008) | The paper reports a population model for nadroparin with explicit numeric values for clearance (CL=23.0 mL/min) and central volume (V1=7.0 L) in the abstract. |

<sub>queue written 2026-09-05T20:20:53.458612+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Romano_2023 | relevant | 10 | 2 | The paper is a population PK study of nadroparin, but the specific numeric parameter values (e.g., typical CL, V, ka) are not present in the provided abstract text. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-09-05 20:27 UTC</sub>
